Retatrutide vs Mazdutide: Comparing Triple and Dual GLP-1/GCGR Agents
The metabolic drug pipeline has moved decisively beyond single-target GLP-1 receptor agonists. While tirzepatide proved that dual agonism could outperform mono-agonists, the next generation of candidates is pushing further — adding glucagon receptor (GCGR) activity to the equation. Two molecules at the forefront of this evolution are retatrutide (LY3437943), a GLP-1/GIP/GCGR triple agonist developed by Eli Lilly, and mazdutide (LY3305677/IBI362), a GLP-1/GCGR dual agonist developed by Innovent Biologics in partnership with Eli Lilly.
Both peptides incorporate glucagon receptor agonism — a mechanism once considered counterintuitive for metabolic disease — but they differ fundamentally in their receptor profiles, pharmacology, and clinical positioning. Understanding these differences is critical for researchers tracking the next wave of incretin-based therapeutics.
Why Glucagon? The Counterintuitive Rationale
Glucagon has historically been viewed as the metabolic antagonist of insulin — it raises blood glucose, stimulates hepatic glucose output, and promotes glycogenolysis. On the surface, activating the glucagon receptor seems like the last thing you'd want in a diabetes or obesity drug.
However, glucagon also has potent effects on energy expenditure, lipid oxidation, and hepatic fat metabolism. Research by Habegger et al., 2010 demonstrated that glucagon increases thermogenesis and promotes satiety through central mechanisms independent of GLP-1. In animal models, co-agonism at the GLP-1 and glucagon receptors produced greater weight loss than GLP-1 agonism alone, with the GLP-1 component counterbalancing glucagon's hyperglycemic effects.
The key insight driving both retatrutide and mazdutide is that glucagon's liabilities on glucose homeostasis can be offset by simultaneous GLP-1 receptor activation, while its benefits on energy expenditure and hepatic lipid clearance are preserved or amplified. This pharmacological balancing act is the foundation of both molecules.
Retatrutide: The Triple Agonist Approach
Retatrutide is a single peptide that activates three receptors: GLP-1R, GIPR, and GCGR. It was designed using a modified GIP backbone with amino acid substitutions conferring activity at all three targets. The molecule includes a fatty acid side chain enabling once-weekly dosing through albumin binding and slowed renal clearance.
The landmark Phase 2 trial published by Jastreboff et al., 2023 in the New England Journal of Medicine enrolled 338 adults with obesity (BMI ≥30, or ≥27 with comorbidity) and randomized them to placebo or escalating doses of retatrutide up to 12 mg weekly for 48 weeks. The results were unprecedented:
A parallel Phase 2 study in participants with type 2 diabetes by Rosenstock et al., 202301053-X) showed HbA1c reductions of up to 2.16% and weight loss of 16.9% at 36 weeks in the 12 mg group. Notably, hepatic fat content decreased by over 80% in a subgroup analysis, suggesting powerful effects on metabolic-associated steatotic liver disease (MASLD).
Retatrutide is now in Phase 3 trials, including the TRIUMPH program (NCT05929066), evaluating outcomes in obesity, type 2 diabetes, and MASLD.
Mazdutide: The Dual Agonist Strategy
Mazdutide activates two receptors — GLP-1R and GCGR — omitting GIP receptor agonism entirely. Developed initially through the Eli Lilly/Innovent collaboration, mazdutide is now primarily advanced by Innovent Biologics for the Chinese and global markets. Its design reflects a hypothesis that the GLP-1/glucagon axis alone may be sufficient for robust metabolic benefit, particularly in hepatic fat reduction.
The Phase 3 GLORY-1 trial, published by Ji et al., 202401306-2) in The Lancet, evaluated mazdutide at doses of 4 mg and 6 mg once weekly in Chinese adults with obesity over 48 weeks. Key results included:
Additional data from Phase 2 studies in type 2 diabetes, published by Ji et al., 202300249-X), showed HbA1c reductions of approximately 1.5% and meaningful weight loss. Innovent has also initiated studies specifically examining mazdutide in MASLD populations, capitalizing on glucagon's established role in hepatic lipid mobilization.
Head-to-Head Comparison: Key Differentiators
While no direct comparative trial exists between these two agents, several important distinctions emerge from their respective datasets and designs.
Receptor Profile and Weight Loss Magnitude:
Hepatic and Metabolic Effects:
Safety and Tolerability:
Development Stage and Market Positioning:
The Glucagon Receptor Question
A central unresolved question in the field is whether GIP receptor agonism adds meaningful benefit when glucagon receptor agonism is already present. Tirzepatide (GLP-1/GIP) demonstrated that GIP agonism synergizes powerfully with GLP-1. Retatrutide layers glucagon on top of that dual agonism. Mazdutide, by contrast, bets that GLP-1 plus glucagon is the more efficient minimal combination.
Preclinical work by Day et al., 2019 suggests that the optimal receptor activation ratio matters as much as which receptors are engaged. The relative potency at each receptor — and how that ratio shifts across different tissues — may ultimately determine clinical differentiation.
Long-term Phase 3 data, MASLD-specific outcomes, and eventual cardiovascular outcomes trials will be required to definitively position these molecules relative to each other and to the broader competitive landscape including tirzepatide, semaglutide, survodutide (another GLP-1/GCGR dual agonist from Boehringer Ingelheim), and orforglipron.